The Direct Answer
Post-COVID anxiety is not simply worry about being ill. It has specific neurobiological drivers including autonomic nervous system dysregulation, neuroinflammation, HPA axis disruption, and serotonin system impairment. The special mushroom supplements with the strongest evidence for these mechanisms are lion's mane (neuroinflammation, NGF), reishi (GABA modulation, cortisol), and psilocybin (serotonin 2A agonism, DMN modulation). Each addresses a different aspect of the post-COVID anxiety picture.
How Common Is Post-COVID Anxiety?
Anxiety is one of the most prevalent long COVID symptoms:
- A 2022 meta-analysis found that 40% of long COVID patients met criteria for an anxiety disorder at 3–6 months post-infection
- Long COVID patients are 2.6 times more likely to develop a new anxiety disorder than COVID patients who fully recovered (Lancet, 2023)
- Anxiety in long COVID is strongly correlated with autonomic symptoms — patients with POTS (postural orthostatic tachycardia syndrome) have particularly high rates of anxiety
- Anxiety and depression co-occur in approximately 70% of long COVID mental health cases
The Neurobiological Mechanisms
| Mechanism | How It Causes Anxiety | Mushroom That Addresses It |
|---|---|---|
| Autonomic nervous system dysregulation | Sympathetic overdrive → racing heart, breathlessness, hypervigilance | Reishi (vagal tone support) |
| Neuroinflammation (IL-6, TNF-α) | Disrupts GABA and serotonin signalling; activates threat-detection circuits | Lion's mane, reishi |
| HPA axis dysregulation | Abnormal cortisol patterns → chronic stress response activation | Reishi (adaptogenic cortisol modulation) |
| Serotonin depletion | Reduced 5-HT signalling in amygdala and prefrontal cortex | Psilocybin (5-HT2A agonism) |
| Default mode network hyperactivity | Excessive self-referential processing → worry, rumination | Psilocybin (DMN modulation) |
Lion's Mane for Post-COVID Anxiety
Lion's mane reduces neuroinflammation through multiple pathways, including inhibition of NF-κB signalling and reduction of pro-inflammatory cytokine expression. Since neuroinflammation disrupts GABA and serotonin signalling — the two primary inhibitory neurotransmitter systems involved in anxiety — reducing neuroinflammation can have downstream anxiolytic effects.
A 2010 randomised trial found that lion's mane supplementation significantly reduced anxiety and depression scores in women over 4 weeks. A 2023 study found improvements in anxiety symptoms alongside cognitive improvements in adults with mild cognitive impairment.
Reishi for Post-COVID Anxiety
Reishi (Ganoderma lucidum) has documented effects on the GABA system — the brain's primary inhibitory neurotransmitter system. Reishi triterpenes have been shown to modulate GABA-A receptors, producing anxiolytic effects similar to (but milder than) benzodiazepines without the dependency risk.
Reishi also has adaptogenic effects on the HPA axis, helping to normalise cortisol patterns. For long COVID patients with dysregulated cortisol rhythms — which are common — this may help restore a more normal stress response.
Psilocybin for Post-COVID Anxiety
Psilocybin's anxiolytic effects are among the most well-documented in psychedelic research. The mechanisms are particularly relevant to post-COVID anxiety:
- 5-HT2A agonism in the amygdala reduces threat-detection hyperactivity
- DMN disruption reduces the ruminative worry that characterises anxiety
- Increased psychological flexibility reduces the rigid threat-appraisal patterns that maintain anxiety
According to Shrooomz's microdosing protocol, the anxiolytic effects of psilocybin microdosing are typically most noticeable in the first 2–4 weeks, with the neuroplasticity effects building over 8–12 weeks. For post-COVID anxiety specifically, the anti-inflammatory component may take longer to manifest.
Related reading: Microdosing psilocybin for anxiety | Long COVID depression | Reishi and sleep
Related Guide
Best Supplements for Long COVID Brain Fog 2026 — Ranked →Lion's mane + cordyceps ranked #1. Full comparison table with clinical evidence per ingredient.
Ready to experience the difference?
Shop Secret Shrooomz →Frequently Asked Questions
Can mushroom supplements treat post-COVID anxiety?
Direct evidence for post-COVID anxiety is limited. Psilocybin-assisted therapy has produced meaningful anxiety reductions in other conditions (notably cancer-related distress) in randomized trials, but there are no large trials focused on post-COVID anxiety yet. Lion's mane and reishi show mechanistic promise (neuroinflammation, NGF; cortisol modulation), but robust anxiety-specific data in post-COVID are lacking.
How strong is the evidence for psilocybin in anxiety?
In clinical populations, psilocybin has demonstrated substantial and sometimes lasting reductions in anxiety and depression (e.g., cancer-related existential distress) in randomized trials. These findings come from relatively small samples and require replication, regulatory allowances, and controlled settings. Safety and access issues mean it is not yet standard care outside of approved research.
Are lion's mane and reishi helpful for post-COVID anxiety?
They target mechanisms implicated in anxiety, such as neuroinflammation and HPA-axis regulation, but direct post-COVID anxiety trials are scarce. Most human evidence comes from non-COVID populations or preclinical work, so the applicability to long-COVID anxiety remains unproven.
Are these supplements safe?
Generally safe for healthy adults at standard doses, but mushrooms can cause GI upset or allergic reactions and product quality varies. Psilocybin-containing preparations are typically illegal outside licensed research and require professional supervision due to safety and psychological risks.
Should I use these now or wait for more evidence?
Discuss with a clinician and consider enrolling in a research trial if available. Do not replace evidence-based treatments for anxiety with mushrooms outside supervised settings, especially for post-COVID symptoms.
Where can I read credible sources about this?
Look for meta-analyses on long COVID anxiety (about 40% prevalence or ~2.6× higher risk for new anxiety disorders, Lancet 2023) and randomized psilocybin trials in anxiety/depression (e.g., cancer-related distress; Griffiths et al., 2016). For mechanistic claims on lion's mane and reishi, seek peer-reviewed reviews and clinical studies addressing NGF, inflammation, and cortisol modulation.